Senescence is a cellular response to a variety of stress signals that is characterized by a
stable withdrawal from the cell cycle and major changes in cell morphology and physiology …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

The accumulation of senescent cells is a major cause of age-related inflammation and
predisposes to a variety of age-related diseases. However, little is known about the …

The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However,
whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is …